Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.
COVID-19
Health equity
Vaccine distribution
global governance
public health justice
public health security
therapeutics
vaccine access
vaccine development
vaccine technologies
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
06
06
2021
revised:
12
07
2021
accepted:
13
07
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
ppublish
Résumé
A Lancet Commission for COVID-19 task force is shaping recommendations to achieve vaccine and therapeutics access, justice, and equity. This includes ensuring
Identifiants
pubmed: 34368661
doi: 10.1016/j.eclinm.2021.101053
pii: S2589-5370(21)00333-3
pmc: PMC8330385
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
101053Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
MEB and PJH are developers of a COVID-19 vaccine construct, which was licensed by Baylor College of Medicine to Biological E Ltd., a commercial vaccine manufacturer for scale up, production, testing and licensure. MG participates in one of eight SARS-CoV-2 vaccine development projects supported by The Scientific and Technological Research Council of Turkey (TÜBİTAK) since March 2020. SG is cofounder of Vaccitech and has a patent on ChAdOx1 nCoV-19 licensed to AstraZeneca. MH is Founder and Managing Director of SaudiVax. JPF, GK and DCK are members of the WHO SAGE Working Group on COVID-19 vaccines. GK is independent director appointed by the Wellcome Trust, MSD Wellcome Trust Hilleman Laboratories Private Limited and Vice Chair of the Board, Coalition of Epidemic Preparedness Innovations (CEPI). DCK reports grants from Bill and Melinda Gates Foundation (BMGF) and grants from CEPI, JHK reports personal fees from SK biosciences. HL reports grants and honoraria from GlaxoSmithKline for training talks and from Merck as a member of the Merck Vaccine Confidence Advisory Board, grants from J&J outside the submitted work. AWS serves as Consultant to WHO. The views presented here reflect her views and not necessarily those of WHO. TS reports grants from National Institute of Allergy and Infectious Disease and Fast Grants and research contracts from GlaxoSmithKline, and ViiV Healthcare. SS reports grants from Ansun BioPharma, Astellas Pharma, Cidara Therapeutics, F2G, Merck, T2 Biosystems, Shire Pharmaceuticals, Shionogi, and Gilead Sciences, outside the submitted work; and personal fees from Amplyx Pharmaceuticals, Acidophil, Janssen Pharmaceuticals, Reviral, Intermountain Healthcare, Karyopharm Therapeutics, Immunome, Celltrion, and Adagio outside the submitted work. All other authors declare no conflict of interests. The authors views and opinions in the Commentary do not necessarily represent the views, decisions, or policies of the institutions, universities, or health systems with which they are affiliated.
Références
PLoS Med. 2012;9(10):e1001327
pubmed: 23109912
Res Social Adm Pharm. 2020 Nov;16(11):1614-1618
pubmed: 32893133
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Am J Public Health. 2018 Oct;108(10):1378-1384
pubmed: 30138075
Nature. 2021 Apr;592(7856):661
pubmed: 33907330
Int J Mol Sci. 2021 May 21;22(11):
pubmed: 34063964
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Nat Med. 2021 Feb;27(2):205-211
pubmed: 33469205
Vaccine. 2020 Nov 25;38(50):7880-7882
pubmed: 33121842
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
SN Compr Clin Med. 2020;2(12):2637-2646
pubmed: 33163859
Lancet. 2020 Oct 10;396(10257):1069-1070
pubmed: 33038965
JAMA. 2021 Apr 6;325(13):1241-1243
pubmed: 33729423
JAMA. 2020 Jul 28;324(4):335-336
pubmed: 32525519
JAMA Netw Open. 2021 Oct 1;4(10):e2128391
pubmed: 34613401
JAMA. 2021 Jun 15;325(23):2337-2338
pubmed: 34047758
J Adv Manuf Process. 2020 Jul;2(3):e10060
pubmed: 33977274
Expert Rev Vaccines. 2020 Oct;19(10):919-936
pubmed: 32940090
Am J Prev Med. 2020 Oct;59(4):493-503
pubmed: 32778354
Immunology. 2019 Jan;156(1):33-46
pubmed: 30317555
Lancet Glob Health. 2021 Jul;9(7):e1017-e1021
pubmed: 33780663
Lancet. 2020 Sep 26;396(10255):898-908
pubmed: 32919524
J Infect Dis. 2019 Apr 8;219(Suppl_1):S97-S106
pubmed: 30715348
Lancet. 2021 Feb 13;397(10274):562-564
pubmed: 33516284
EClinicalMedicine. 2021 Mar;33:100780
pubmed: 33718854
Mayo Clin Proc. 2021 May;96(5):1262-1275
pubmed: 33958057
EClinicalMedicine. 2021 Jun;36:100925
pubmed: 34099998